At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 558 enrolled
Drug / intervention
ISV-305 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis
In Brief
A Phase 3 clinical trial evaluating ISV-305 and Vehicle for Active, Symptomatic Blepharitis. Completed, enrolled 558 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActive, Symptomatic Blepharitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartMar 2018
Primary CompletionFeb 2020
TodayJul 2026
First PostedMar 5, 2012
Enrollment StartMar 30, 2018
Primary CompletionFeb 4, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.3 years ago
Interventions
ISV-305drug
Dexamethasone in DuraSite® 2 twice daily for 2 weeks
Vehicleother
Vehicle twice daily for 2 weeks